The new guidelines say healthcare providers should consider medical interventions such as GLP-1RAs and bariatric surgery while avoiding stigmatizing language when discussing obesity.
Patients using icodec tend to have a higher incidence of hypoglycemic events compared to glargine or degludec, especially on days 2–4 of the weekly dosing cycle.
Dr. Daniel Drucker, an endocrinologist and a clinician-scientist at the University of Toronto and the Lunenfeld-Tanenbaum Research Institute at Sinai Health, shares the US$3 million prize with four colleagues.
